Peripheral T-cell lymphoma: Novel backbone

Julie M. Vose

doi:10.1182/blood-2017-11-817734

Peripheral T-cell lymphoma: Novel backbone

Julie M. Vose

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL)¹.

Original language	English (US)
Pages (from-to)	375-376
Number of pages	2
Journal	Blood
Volume	131
Issue number	4
DOIs	https://doi.org/10.1182/blood-2017-11-817734
State	Published - Jan 25 2018

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2017-11-817734

Cite this

@article{40ed183da9dd4bc2b5cbcddbb09e446e,

title = "Peripheral T-cell lymphoma: Novel backbone",

abstract = "In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL)1.",

author = "Vose, {Julie M.}",

note = "Publisher Copyright: {\textcopyright} 2018 by The American Society of Hematology.",

year = "2018",

month = jan,

day = "25",

doi = "10.1182/blood-2017-11-817734",

language = "English (US)",

volume = "131",

pages = "375--376",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Peripheral T-cell lymphoma

T2 - Novel backbone

AU - Vose, Julie M.

PY - 2018/1/25

Y1 - 2018/1/25

N2 - In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL)1.

AB - In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL)1.

UR - http://www.scopus.com/inward/record.url?scp=85041051359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041051359&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-11-817734

DO - 10.1182/blood-2017-11-817734

M3 - Review article

C2 - 29371206

AN - SCOPUS:85041051359

SN - 0006-4971

VL - 131

SP - 375

EP - 376

JO - Blood

JF - Blood

IS - 4

ER -

Peripheral T-cell lymphoma: Novel backbone

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this